The math is stark, if a little hard to believe: Crop pests that have evolved resistance to conventional insecticides now cost U.S. agriculture an estimated $10 billion a year—a figure commonly cited in the industry, though researchers note uncertainty and the need for updated quantification. More than 550 arthropod species have documented resistance, turning what was once routine pest management into something closer to a chemical treadmill—spray harder, spray more often, watch efficacy slip away.
It's a crisis that has been years in the making, and it arrives just as regulatory scrutiny tightens around broad-spectrum chemistries and pollinator declines dominate headlines. Into this tight spot, a new generation of molecularly-targeted biopesticides is making a pitch: precision without the inevitable resistance spiral.
Whether that promise holds up remains an open question. But the market is already placing its bets.
A Market Heating Up
The biopesticides sector is approaching what analysts like to call an inflection point, though the numbers vary depending on who's counting. Fortune Business Insights has estimated the market at $9.91 billion in 2025, with projections climbing toward $40.61 billion by 2034—a compound annual growth rate of 17.11%. Grand View Research has charted a more conservative trajectory, landing closer to $26 billion in the early 2030s. Research & Markets falls somewhere in between.
The variance reflects different scopes and regional definitions more than disagreement about direction. Everyone sees double-digit growth, driven by a trifecta of pressure: tougher regulations, retailer mandates that favor cleaner chemistries, and the simple inadequacy of tools that no longer work the way they used to.
Regulatory Walls Closing In
The Environmental Protection Agency has spent the past few years reshaping what farmers can apply, and where. A multi-year push to protect endangered species—mandated by Endangered Species Act litigation—has produced a cascade of frameworks. The agency finalized its Herbicide Strategy in late 2024 to safeguard roughly 900 species, followed by an Insecticide Strategy in early 2025. A draft Fungicide Strategy opened for public comment in mid-2026, with the comment window closing at the end of June.
These frameworks increasingly favor selective tools that can sidestep the kind of landscape-level mitigations that broad-spectrum chemistries trigger. It's regulatory architecture that, intentionally or not, tilts the playing field toward biologicals.
State-level action has been sharper, more direct. California implemented neonicotinoid restrictions for agriculture at the start of 2024, with non-agricultural outdoor and consumer restrictions following a year later under AB 363. New York's "Birds and Bees Protection Act," signed in December 2023, phases in seed-treatment and other neonic restrictions through 2026. The EPA's updated Pollinator Risk Assessment Guidance, refreshed in mid-2026, signals that pollinator safety has graduated from secondary consideration to front-of-mind priority.
Then there are the retailers. Walmart set a requirement for 100% of its fresh produce and floral suppliers to use third-party-verified integrated pest management programs by 2025, according to its environmental, social, and governance commodity reporting. Target has set pollinator-related guidance to reduce neonicotinoid exposure in live plants and established a soil-health goal covering one million acres—targets it updated in recent reporting.
Retailers, it turns out, can move faster than regulators.
From Fungal Sprays to Computational Proteins
Biopesticides have long been synonymous with microbes: bacteria, fungi, viruses deployed in the field. Several market reports still list microbial products as the largest segment, and for good reason. FAO-guided trials using the fungus Metarhizium acridum for locust control have run in Kyrgyzstan and Mauritania in recent years, demonstrating the staying power of entomopathogenic fungi in operational pest management. Semiochemicals—particularly pheromone-based mating disruption for codling moth and orchard pests—have carved out a reliable niche. Bayer expanded its global distribution partnership with the French firm M2i Group in mid-2025 to scale pheromone-based biological solutions.
But a newer wave is gaining traction, one that relies on macromolecular precision rather than living organisms. Formulations have improved. Regulatory precedents are accumulating.
Biotalys secured EPA approval in late 2025 for EVOCA, billed as the first-of-its-kind protein biofungicide. The Belgian company announced a partnership the following year with 21st.BIO for scale-up and has set its sights on U.S. registration of a next-generation product by the late 2020s, with European Union and Brazil approvals targeted for a similar timeframe.
RNAi-based sprays represent another frontier, still narrow but expanding. GreenLight Biosciences developed ledprona (marketed as Calantha), which targets the proteasome subunit PSMB5 in Colorado potato beetles. Cornell researchers found in late 2025 that efficacy peaks when larvae are small—a detail that matters in the field. New York's Department of Environmental Conservation has capped applications at two per season to slow resistance selection, a precaution that suggests regulators are learning from the chemical treadmill. Multicenter trials evaluated non-target arthropod impacts, and an EPA research committee noted in meeting summaries that ledprona represents the first sprayable dsRNA tool, signaling potentially faster review timelines for some biologicals.
Vestaron, which develops peptides derived from spider venom, raised over $20 million in an oversubscribed funding round in early 2025 to scale its portfolio. The company secured emergency use authorizations for its SPEAR LEP product across multiple EU countries and launched BASIN FLEX around the same time. A partnership announced in late 2025 with American Pistachio Growers integrates SPEAR LEP for navel orangeworm control, backed by peer-reviewed research on orally active peptide stabilization.
The Startup Pitch: Resistance-Free by Design
It's in this landscape that Molagri is making its entrance. The Toronto-based startup, part of Y Combinator's Summer 2026 cohort, is positioning what it calls "resistance-free pesticides"—a bold claim in an industry where resistance is typically treated as inevitable, only a matter of time.
The company's pitch, as described in its Y Combinator profile, centers on biopesticides that hit precise molecular targets unique to pest insects. The idea is to spare pollinators and beneficial insects while using evolutionary modeling to anticipate and outmaneuver resistance before it develops. Founders Zaky Hassan and Min Jin are University of Toronto PhD lab mates with publications in Nature Communications and Nature Microbiology, according to the YC directory—academic credentials that matter in a field where molecular biology meets commercial agriculture.
Molagri's LinkedIn presence emphasizes "precision biopesticides using protein design" and frames the tools as safer for humans and the environment. The company has posted hiring notices for a scientist role in protein biochemistry and engineering and a research associate position in Toronto, with salaries listed in the range of CAD 75,000 to 85,000. Early posts credit support from Julian Capital, a deeptech seed investor, though no explicit portfolio listing appeared on Julian Capital's site as of mid-2026. Federal incorporation records in Canada list Molagri Inc. with director Zaky Hassan.
The framing—resistance
